Rani Therapeutics Holdings (RANI) Cash from Investing Activities (2020 - 2026)

Rani Therapeutics Holdings' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$2.4 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 113.44% year-over-year to -$2.4 million in Q1 2026; TTM through Mar 2026 was -$27.7 million, a 199.87% decrease from a year earlier, with the FY2025 full-year figure at -$7.0 million, down 135.49% from the prior year.
• Cash from Investing Activities climbed to -$2.4 million in Q1 2026 per RANI's latest filing, from -$31.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $18.2 million in Q1 2025 and bottomed at -$71.3 million in Q3 2022.
• The 5-year median for Cash from Investing Activities is $1.7 million (2023), against an average of -$2.0 million.
• Across the five-year window, Cash from Investing Activities soared 3004.6% in 2023 and plunged 1328.56% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at -$457000.0 in 2022, then surged by 3004.6% to $13.3 million in 2023, then tumbled by 81.01% to $2.5 million in 2024, then plunged by 1328.56% to -$31.0 million in 2025, then jumped by 92.09% to -$2.4 million in 2026.
• Per Business Quant, the three latest RANI Cash from Investing Activities figures stand at -$2.4 million (Q1 2026), -$31.0 million (Q4 2025), and $5.7 million (Q2 2025).